Top 50 Global Biopharma Companies Dealmaking Reviewed in New Topical Report Published at MarketPublishers.com
21 Jun 2012 • by Natalie Aster
LONDON – What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subscontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? The answers to all these questions and many more can be found in the research report.
New research report “Partnering Agreements with Bigpharma 2012” worked out by CurrentPartnering has been recently published by Market Publishers Ltd.
Partnering Agreements with Bigpharma 2012
Published: June, 2012
Price: US$ 2.695,00
The research report is aimed to provide an in-depth understanding of the dealmaking interests and activity of the top fifty biopharma companies the world over.
More new research reports by the publisher can be found at CurrentPartnering page.